Oppenheimer started coverage with USD 27.00 target for Amneal Pharmaceuticals stock

Published on 10/17/2026 at 19:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Results are due November 3, 2026. Amneal Pharmaceuticals stock last stood at EUR 17.60 on October 16, 2026, down 2.22 percent versus the Tradegate close.

Analyst view and trading date

Oppenheimer initiated coverage with a USD 27.00 target on September 23, 2026.
Amneal Pharmaceuticals will report third-quarter results on November 3, 2026.
Amneal Pharmaceuticals stock last stood at EUR 17.60 at Tradegate on October 16, 2026 at 8:03 p.m. CEST, down 2.22 percent versus the Tradegate close.
Amneal Pharmaceuticals had a P/E ratio of 39.34 as of October 16, 2026.

AMRX, US03168L1052, Illustration mit AI erstellt.

Oppenheimer initiated coverage of Amneal Pharmaceuticals with an Outperform rating and a USD 27.00 price target on September 23, 2026, implying 40.77 percent upside to the USD 19.18 Nasdaq price on October 16, 2026, based on the target calculation reported by Investing.com. Amneal will report third-quarter 2026 results on November 3, 2026, before the Nasdaq market opens, according to Amneal Pharmaceuticals. The last Tradegate quote was EUR 17.60 on October 16, 2026 at 8:03 p.m. CEST, down 2.22 percent versus the Tradegate close.

Second-quarter growth sets the backdrop

Amneal entered the autumn reporting cycle after second-quarter revenue reached USD 796.2 million, up 10 percent year over year. Adjusted earnings per share came to USD 0.30, up 20 percent from the prior-year quarter, while adjusted EBITDA reached USD 206 million, up 12 percent, according to the Yahoo Finance transcript dated July 30, 2026. The figures give the November release a clear comparison point, particularly after management raised its 2026 revenue outlook to USD 3.1 billion to USD 3.2 billion.

Amneal stock remains below its high

On Nasdaq, Amneal last traded at USD 19.18 on October 16, 2026 at 4:00 p.m. ET. The same quote stood 9.45 percent below the 52-week high of USD 21.18 and 93.55 percent above the low of USD 9.92. Trading volume was 2,286,719 shares against an average of 2,442,701.

Valuation and November 3 results

Amneal carried a market capitalization of USD 6.1 billion and a P/E ratio of 39.34 as of October 16, 2026. Its dividend yield was 0.00 percent. The scheduled November 3 report will provide the next company-specific earnings comparison and will include a webcast at 8:30 a.m. ET.

Comparison with peers

Amneal Pharmaceuticals (Tradegate, EUR): down 2.22 percent, P/E 39.34, market capitalization USD 6.1 billion
Amgen (Nasdaq, USD): down 0.35 percent, P/E 26.88, market capitalization USD 233.8 billion
Viatris (Nasdaq, USD): up 2.39 percent, P/E minus 51.82, market capitalization USD 21.4 billion